Loading
A phase 3 trial testing Purinostat in diffuse large B-cell lymphoma, now recruiting.
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma is a phase 3 interventional study registered as NCT07011056, led by Chengdu Zenitar Biomedical Technology, and recruiting on the registry. Official title: A Randomised, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of the Purinostat Mesylate for Injection (PM) Compared to Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). Planned enrolment is 390 participants (estimated). The study started in 2025-07-18 and primary completion is expected in 2029-06-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Chengdu Zenitar Biomedical Technology, Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/